Processa Pharmaceuticals filings document formal 8-K and amended 8-K disclosures for a clinical-stage biopharmaceutical issuer. The records cover material events involving licensing and term-sheet matters, Nasdaq listing compliance, executive-officer status changes and compensatory arrangements, and shareholder-vote reporting.
The company's filings also describe capital-structure and charter actions, including amendments to its certificate of incorporation, authorized-share changes, reverse stock split mechanics, common-stock rights and related governance approvals. These disclosures frame Processa's public-company status, equity structure and corporate governance alongside its development-stage pharmaceutical business.
Processa Pharmaceuticals filed an amendment to a Schedule 13G/A reporting that CVI Investments, Inc. and its investment manager Heights Capital Management, Inc. beneficially own 200,000 shares of common stock, representing 7.0% of the class. The filing notes these shares consist of warrants and cites 2,677,835 Shares outstanding as of March 31, 2026.
The joint filing clarifies that Heights Capital Management serves as investment manager to CVI Investments and may exercise voting and dispositive power; both Reporting Persons disclaim beneficial ownership except for pecuniary interest. Signatures are dated May 13, 2026.
Processa Pharmaceuticals director and executive David Young reported buying additional common stock. On April 30, 2026, he made an open-market purchase of 1,706 shares at $2.69 per share, bringing his direct holdings to 13,813 shares. He also reports indirect ownership of 742 shares through CorLyst, LLC, 432 shares through family entities, and 1,242 shares through the Young-Plaisance Revocable Trust.
Processa Pharmaceuticals, Inc. Chief Financial Officer Russell Skibsted made an open-market purchase of the company’s Common Stock. On the reported date, he bought 2,190 shares at a price of $2.69 per share and, after this transaction, directly held a total of 6,498 shares.
Processa Pharmaceuticals, Inc. director and Chief Executive Officer George K. Ng reported an open-market purchase of 2,034 shares of Common Stock at $2.69 per share. This buy increased his direct ownership to 6,013 shares of Common Stock.
As of the transaction date, he also reported indirect ownership of 800 shares held by the Ng Cha Family Trust and 3,488 shares held under "George Ng IRRA FOB George Ng." All holdings reflect positions as of April 30, 2026.
Processa Pharmaceuticals Chief Business-Strategy Officer Patrick Lin bought 1,511 shares of common stock in an open-market purchase at $2.69 per share. After this transaction, he directly owns 6,236 shares and indirectly holds 1,740 shares through the Lin Family Trust Feb 4, 2024.
Processa Pharmaceuticals Chief Administrative Officer Wendy Guy reported an open-market purchase of the company’s common stock. On April 30, 2026, she bought 1,748 shares of Processa Pharmaceuticals, Inc. common stock at $2.69 per share in a direct transaction.
Following this purchase, she directly owns 6,441 common shares. The filing also lists an indirect holding of 333 common shares described as held "By CorLyst, LLC," reflecting a separate ownership line associated with her.
Processa Pharmaceuticals Chief Development Officer buys shares on the open market. Reporting person Sian Bigora acquired 1,986 shares of Processa Pharmaceuticals common stock in an open-market purchase at $2.69 per share, bringing direct holdings to 7,496 shares. The filing also shows 267 shares of common stock held indirectly through CorLyst, LLC.
Processa Pharmaceuticals, Inc. filed Amendment No. 1 to its annual report for the year ended December 31, 2025 to add updated Part III information on governance, executive pay, ownership and auditor fees. The company reports a non-affiliate equity market value of about $8.1 million as of June 30, 2025 and 2,738,998 common shares outstanding as of April 29, 2026.
The amendment details board and committee composition, independence determinations, meeting activity in 2025, and compensation for key executives and directors, including salaries, bonuses and equity awards. It also outlines employment and severance terms, equity plan capacity, major shareholders, related-party arrangements and audit fees for 2024 and 2025.
Processa Pharmaceuticals is changing the role of Dr. Sian Bigora as she moves toward retirement. Effective May 1, 2026, she will shift from a full-time executive officer position to a part-time employee role but will retain her title of Chief Development and Regulatory Officer.
After this change, she will no longer be treated as an “executive officer” under Section 16 of the Exchange Act, yet she will continue providing services in a reduced capacity. Her current employment agreement will end and be replaced with a new part-time arrangement, while she keeps previously granted equity awards and remains eligible for any prior bonus awards under their original terms.